不稳定型心绞痛和非ST段抬高心梗治疗.pptVIP

Acute Coronary Syndromes: Management of UA/NSTEMI;Overview of 2003 Updates to the ACC/AHA Guideline for UA/NSTEMI;Acute Management of UA/NSTEMI;Possible ACS;17.1;Aspirin in Acute Coronary Syndromes;Indirect Comparisons of ASA Doses on Vascular Events in High-Risk Patients;BRAVO: Bleeding By ASA dose;Clopidogrel + ASA? (N=6259);RR: Death/MI;TIMI, Thrombosis in Myocardial Infarction; ESSENCE, Efficacy and Safety of Subcutaneous Enozapam in Non–Q-Wave Coronary Events; UHF, unfractionated heparin; ENOX, enoxaparin; MI, myocardial infarction; OR, odds ratio. Antman EM, et al. Circulation. 1999;100:1602-1608. (with permission); ;UFH;A-Phase Study Design;0;Enox Test vs Outcomes;Direct Thrombin Inhibitor Trialists Collaboration;Early invasive strategy;GP IIb/IIIa Inhibitor During Medical Management and After PCI: CAPTURE, PURSUIT, PRISM-PLUS;Meta-analysis of IIb/IIIa Inhibition in PCI for 30-Day Mortality;IV GP IIb/IIIa Inhibitors in ACS: Death or MI at 30 Days (N=31,402);Benefit of IIb/IIIa inhibitors in UA/NSTEMI by Troponin;GP IIb/IIIa Inhibition in TnI + Patients by Revascularization: PRISM Study;GP IIb/IIIa Inhibition in Diabetics ;Intravenous GP IIb/IIIa Antagonists in ACS: Death or MI (at 30 Days) in PCI/CABG 5 Days Cohort and in Medical Treatment Cohort;GP Iib/IIIa Inhibitor NSTE ACS Trials Analysis Risk-Adjusted Mortality at 30 Days;Mortality by Hospitals’ Use of Early GP IIb/IIIa Inhibitors (N=1189 Hospitals);Efficacy of Clopidogrel or Ticlopidine in Reducing Coronary Events After Stenting; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events; MI, myocardial infarction; CV, cardiovascular; RRR, relative risk reduction. ? Plavix? [package insert]; 2002. Adapted with permission (2002) from the Massachusetts Medical Society. Yusuf S, et al. N Engl J Med. 2001;345:494-502.;CURE: MI/Stroke/CV Death/Severe Ischemia Within 24 Hours of Randomization; CURE, clopidogrel in Unstable Angina to Prevent Ischemic Events; TIMI, Thrombosis in My